埃格列净与CKD合并糖尿病患者肾损伤、炎症及纤维化标志物的关联
本文为VERTIS RENAL试验的事后探索性分析,纳入2型糖尿病合并3期CKD患者,随机接受埃格列净(5或15 mg/d)或安慰剂,检测基线、26周和52周血浆标志物。结果显示埃格列净组KIM-1在26周和52周均较低,52周时eotaxin-1较高,KIM-1变化与UACR变化正相关,其他标志物无显著关联。
要点
- 埃格列净可持续降低2型糖尿病合并3期CKD患者的肾小管损伤标志物KIM-1。
- KIM-1降低不依赖基线eGFR或UACR,且其变化与UACR变化正相关。
- 其他肾小管损伤、炎症、纤维化、氧化应激及内皮功能障碍标志物无显著变化。
核心结论
- 在2型糖尿病合并3期CKD患者中,埃格列净与肾小管损伤标志物KIM-1的持续降低相关,且不依赖基线肾功能。
研究设计与样本
- VERTIS RENAL试验的事后探索性分析,参与者随机接受埃格列净5或15 mg/d或安慰剂,并在基线、26周和52周采集血浆进行生物标志物分析。
主要发现
- 与安慰剂相比,埃格列净组26周(P=0.044)和52周(P=0.007)血浆KIM-1水平较低,52周eotaxin-1较高(P=0.007)。
- KIM-1变化与基线UACR或eGFR无交互作用(P交互>0.05)。
- 在埃格列净组中,KIM-1变化与UACR变化呈正相关(P=0.0071)。
- 其他肾小管损伤、炎症、纤维化、氧化应激及内皮功能障碍标志物未见显著关联。
临床怎么用
- 对于2型糖尿病合并3期CKD患者,埃格列净可能通过降低肾小管损伤标志物KIM-1发挥肾脏保护作用。
局限性
- 本研究为事后探索性分析,结果需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Sodium-glucose cotransporter-2 (SGLT2) inhibitors improve cardiovascular and kidney outcomes through mechanisms that are incompletely understood. In this exploratory post-hoc analysis of the VERTIS RENAL trial, we report the association between the SGLT2 inhibitor, ertugliflozin, and markers of kidney injury, inflammation, and fibrosis in participants with type 2 diabetes (T2D) and stage 3 chronic kidney disease (CKD). METHODS: Participants were randomized to ertugliflozin (5 or 15 mg/d) or placebo, and plasma samples for biomarker analysis were collected at baseline, 26 weeks, and 52 weeks. RESULTS: Ertugliflozin-treated participants had lower plasma levels of kidney injury molecule-1 (KIM-1) at 26 weeks (P = 0.044) and 52 weeks (P = 0.007) and higher eotaxin-1 at 52 weeks (P = 0.007) postrandomization compared with placebo. The change in KIM-1 was not associated with the baseline urine albumin to creatinine ratio (UACR) or the estimated glomerular filtration rate (eGFR, P interaction > 0.05). Additionally, the change in KIM-1 was positively correlated with the change in UACR in participants treated with ertugliflozin (P = 0.0071). No other significant associations between ertugliflozin and changes in the markers of tubular injury, inflammation, fibrosis, oxidative stress, and endothelial dysfunction were observed. CONCLUSION: In conclusion, in participants with T2D and stage 3 CKD, ertugliflozin was associated with a sustained lowering of the tubular injury marker KIM-1 regardless of baseline kidney function.
引用
- Liu H, Sridhar VS, Lovblom LE, et al. Markers of Kidney Injury, Inflammation, and Fibrosis Associated With Ertugliflozin in Patients With CKD and Diabetes. Kidney Int Rep. 2021. PMID: 34386658. doi:10.1016/j.ekir.2021.05.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。